EASD 2026: TRIUMPH-2 data puts retatrutide above the incretin ceiling in T2D
The trial evaluated Eli Lilly's retatrutide in adults with obesity or overweight and type 2 diabetes.
The trial evaluated Eli Lilly's retatrutide in adults with obesity or overweight and type 2 diabetes.